Table II.
Correlation of NAC1 expression with clinicopathologic factors in prostate cancer.
| Immunointensity, n (%) | ||||
|---|---|---|---|---|
| Factors | Case no. | 0 or 1+ | 2+ or 3+ | P-value |
| Histologic type | <0.001 | |||
| Prostate cancer | 84 | 18 (21) | 66 (79) | |
| Normal prostate | 84 | 62 (74) | 22 (26) | |
| Patients' age | 0.09 | |||
| <60 y | 20 | 7 (35) | 13 (65) | |
| ≥60 y | 64 | 11 (17) | 53 (83) | |
| Clinical stages | 0.002 | |||
| ≤IIb | 38 | 14 (37) | 24 (63) | |
| ≥IIc | 46 | 4 (1) | 42 (99) | |
| Preoperative | 0.878 | |||
| PSA (ng/ml) | ||||
| ≤20 | 48 | 10 (21) | 38 (79) | |
| >20 | 36 | 8 (22) | 28 (78) | |
| Gleason score | 0.437 | |||
| ≤7 | 62 | 12 (19) | 50 (81) | |
| ≥8 | 22 | 6 (27) | 16 (73) | |
NAC1, nucleus accumbens-associated protein 1; PSA, prostate-specific antigen.